Sucroferric oxyhydroxide (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sucroferric oxyhydroxide" in Vietnamese language version.

refsWebsite

Global rank Vietnamese rank

16nih.gov

4^th place

7^th place

10doi.org

2^nd place

1web.archive.org

1^st place

1europa.eu

68^th place

114^th place

doi.org

Chong E, Kalia V, Willsie S, Winkle P (tháng 12 năm 2014). “Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects”. Journal of Nephrology. 27 (6): 659–66. doi:10.1007/s40620-014-0080-1. PMC 4242982. PMID 24699894.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW (tháng 7 năm 2013). “Chronic kidney disease: global dimension and perspectives”. Lancet. 382 (9888): 260–72. doi:10.1016/S0140-6736(13)60687-X. PMID 23727169.
Hutchison AJ, Smith CP, Brenchley PE (tháng 9 năm 2011). “Pharmacology, efficacy and safety of oral phosphate binders”. Nature Reviews. Nephrology. 7 (10): 578–89. doi:10.1038/nrneph.2011.112. PMID 21894188.
Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M (tháng 2 năm 2009). “Phosphorus binders and survival on hemodialysis”. Journal of the American Society of Nephrology. 20 (2): 388–96. doi:10.1681/ASN.2008060609. PMC 2637053. PMID 19092121.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (tháng 8 năm 2009). “KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)”. Kidney International Supplement. 76 (113): S1-130. doi:10.1038/ki.2009.188. PMID 19644521.
Wilhelm M, Gaillard S, Rakov V, Funk F (tháng 4 năm 2014). “The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro”. Clinical Nephrology. 81 (4): 251–8. doi:10.5414/cn108119. PMID 24656315.
Lanz M, Baldischweiler J, Kriwet B, Schill J, Stafford J, Imanidis G (tháng 12 năm 2014). “Chewability testing in the development of a chewable tablet for hyperphosphatemia”. Drug Development and Industrial Pharmacy. 40 (12): 1623–31. doi:10.3109/03639045.2013.838583. PMID 24010939.
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM (tháng 9 năm 2014). “A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients”. Kidney International. 86 (3): 638–47. doi:10.1038/ki.2014.58. PMC 4150998. PMID 24646861.
Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM (tháng 6 năm 2015). “Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients”. Nephrology, Dialysis, Transplantation. 30 (6): 1037–46. doi:10.1093/ndt/gfv006. PMC 4438742. PMID 25691681.
Kalantar-Zadeh K, Parameswaran V, Ficociello LH, Anderson L, Ofsthun NJ, Kwoh C, Mullon C, Kossmann RJ, Coyne DW (2018). “Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide”. American Journal of Nephrology. 47 (3): 153–161. doi:10.1159/000487856. PMC 5906196. PMID 29514139.

europa.eu

ema.europa.eu

“Velphoro (sucroferric oxyhydroxide). Summary of Product Characteristics” (PDF). EMA. Bản gốc lưu trữ ngày 21 tháng 10 năm 2014. Truy cập ngày 24 tháng 10 năm 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Chong E, Kalia V, Willsie S, Winkle P (tháng 12 năm 2014). “Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects”. Journal of Nephrology. 27 (6): 659–66. doi:10.1007/s40620-014-0080-1. PMC 4242982. PMID 24699894.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW (tháng 7 năm 2013). “Chronic kidney disease: global dimension and perspectives”. Lancet. 382 (9888): 260–72. doi:10.1016/S0140-6736(13)60687-X. PMID 23727169.
Hutchison AJ, Smith CP, Brenchley PE (tháng 9 năm 2011). “Pharmacology, efficacy and safety of oral phosphate binders”. Nature Reviews. Nephrology. 7 (10): 578–89. doi:10.1038/nrneph.2011.112. PMID 21894188.
Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M (tháng 2 năm 2009). “Phosphorus binders and survival on hemodialysis”. Journal of the American Society of Nephrology. 20 (2): 388–96. doi:10.1681/ASN.2008060609. PMC 2637053. PMID 19092121.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (tháng 8 năm 2009). “KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)”. Kidney International Supplement. 76 (113): S1-130. doi:10.1038/ki.2009.188. PMID 19644521.
Wilhelm M, Gaillard S, Rakov V, Funk F (tháng 4 năm 2014). “The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro”. Clinical Nephrology. 81 (4): 251–8. doi:10.5414/cn108119. PMID 24656315.
Lanz M, Baldischweiler J, Kriwet B, Schill J, Stafford J, Imanidis G (tháng 12 năm 2014). “Chewability testing in the development of a chewable tablet for hyperphosphatemia”. Drug Development and Industrial Pharmacy. 40 (12): 1623–31. doi:10.3109/03639045.2013.838583. PMID 24010939.
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM (tháng 9 năm 2014). “A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients”. Kidney International. 86 (3): 638–47. doi:10.1038/ki.2014.58. PMC 4150998. PMID 24646861.
Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM (tháng 6 năm 2015). “Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients”. Nephrology, Dialysis, Transplantation. 30 (6): 1037–46. doi:10.1093/ndt/gfv006. PMC 4438742. PMID 25691681.
Kalantar-Zadeh K, Parameswaran V, Ficociello LH, Anderson L, Ofsthun NJ, Kwoh C, Mullon C, Kossmann RJ, Coyne DW (2018). “Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide”. American Journal of Nephrology. 47 (3): 153–161. doi:10.1159/000487856. PMC 5906196. PMID 29514139.

ncbi.nlm.nih.gov

Chong E, Kalia V, Willsie S, Winkle P (tháng 12 năm 2014). “Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects”. Journal of Nephrology. 27 (6): 659–66. doi:10.1007/s40620-014-0080-1. PMC 4242982. PMID 24699894.
Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M (tháng 2 năm 2009). “Phosphorus binders and survival on hemodialysis”. Journal of the American Society of Nephrology. 20 (2): 388–96. doi:10.1681/ASN.2008060609. PMC 2637053. PMID 19092121.
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM (tháng 9 năm 2014). “A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients”. Kidney International. 86 (3): 638–47. doi:10.1038/ki.2014.58. PMC 4150998. PMID 24646861.
Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM (tháng 6 năm 2015). “Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients”. Nephrology, Dialysis, Transplantation. 30 (6): 1037–46. doi:10.1093/ndt/gfv006. PMC 4438742. PMID 25691681.
Kalantar-Zadeh K, Parameswaran V, Ficociello LH, Anderson L, Ofsthun NJ, Kwoh C, Mullon C, Kossmann RJ, Coyne DW (2018). “Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide”. American Journal of Nephrology. 47 (3): 153–161. doi:10.1159/000487856. PMC 5906196. PMID 29514139.

dailymed.nlm.nih.gov

“Highlights of Prescribing information for Velphoro”. Fresenius. tháng 9 năm 2014.

web.archive.org

“Velphoro (sucroferric oxyhydroxide). Summary of Product Characteristics” (PDF). EMA. Bản gốc lưu trữ ngày 21 tháng 10 năm 2014. Truy cập ngày 24 tháng 10 năm 2014.